Lutikizumab Showed Positive Results in a Phase II Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase III
AbbVie has reported the results of Phase II trials indicating that adults experiencing moderate to severe hidradenitis suppurativa, and who had previously not responded to anti-TNF therapy, exhibited higher rates of response (59.5% with a nominal p-value of 0.027 for the 300 mg every other week dosage, and 48.7% with a nominal p-value of 0.197 for the 300 mg weekly dosage) compared to those who received a placebo (35%). The primary endpoint, achieving hidradenitis suppurativa Clinical Response (HiSCR 50) at week 16, was...
